Literature DB >> 3529951

Effects of nonsteroidal anti-inflammatory drugs on proteinuria.

R Vriesendorp, A J Donker, D de Zeeuw, P E de Jong, G K van der Hem, J R Brentjens.   

Abstract

Most nonsteroidal anti-inflammatory drugs are anti-proteinuric agents, especially if the patient is sodium-depleted. The decline in urinary protein excretion induced by these agents always markedly exceeds the decrease in glomerular filtration rate. Moreover, the remaining proteinuria appears to be more selective. Together, these findings suggest that the anti-proteinuric effect of nonsteroidal anti-inflammatory drugs is hemodynamically mediated. Nonsteroidal anti-inflammatory agents that reduce renal prostaglandin E2 excretion also decrease proteinuria, whereas sulindac decreases neither prostaglandin E2 nor protein excretion. In a retrospective study, it appeared that administration of indomethacin improved renal survival of nephrotic patients with an initial serum creatinine concentration of less than 110 mumol/liter. The anti-proteinuric effect of indomethacin itself or indomethacin-induced hemodynamic changes might explain this observation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3529951     DOI: 10.1016/0002-9343(86)90910-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

1.  Prostaglandin E(2) is crucial in the response of podocytes to fluid flow shear stress.

Authors:  Tarak Srivastava; Ellen T McCarthy; Ram Sharma; Patricia A Cudmore; Mukut Sharma; Mark L Johnson; Lynda F Bonewald
Journal:  J Cell Commun Signal       Date:  2010-04-08       Impact factor: 5.782

2.  A maladaptive role for EP4 receptors in podocytes.

Authors:  Erin M Stitt-Cavanagh; Wissam H Faour; Kaede Takami; Anthony Carter; Barbara Vanderhyden; Youfei Guan; Andre Schneider; Matthew D Breyer; Christopher R J Kennedy
Journal:  J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 10.121

Review 3.  Novel drugs and intervention strategies for the treatment of chronic kidney disease.

Authors:  Hiddo Jan Lambers Heerspink; Dick de Zeeuw
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

4.  Management of congenital nephrotic syndrome.

Authors:  Larisa Kovacevic; Christopher J D Reid; Susan P A Rigden
Journal:  Pediatr Nephrol       Date:  2003-04-08       Impact factor: 3.714

Review 5.  Non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function.

Authors:  N D Sturrock; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

Review 6.  Renoprotective therapy in patients with nondiabetic nephropathies.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Hyperfiltration-associated biomechanical forces in glomerular injury and response: Potential role for eicosanoids.

Authors:  Mukut Sharma; Ram Sharma; Ellen T McCarthy; Virginia J Savin; Tarak Srivastava
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-01-17       Impact factor: 3.072

8.  Excretion of metabolites of prostacyclin and thromboxane by rats with nephrotoxic nephritis: effects of interleukin-1.

Authors:  P S Ward; R W Fuller; J M Ritter; S J Cashman; A J Rees; C T Dollery
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

9.  Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme.

Authors:  E J Franssen; R G van Amsterdam; J Visser; F Moolenaar; D de Zeeuw; D K Meijer
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

Review 10.  Prostaglandin inhibitors in the treatment of nephrotic syndrome.

Authors:  J M Bergstein
Journal:  Pediatr Nephrol       Date:  1991-05       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.